Skip to Content
Search Menu

Real-world data on effectiveness of durvalumab after chemoradiotherapy

Real-world data on effectiveness of durvalumab after PACIFIC-R real-world trial confirms effectiveness of durvalumab in patients with unresectable stage III non–small cell lung cancer (NSCLC), concludes Professor Nicolas Girard in this BestPractice Nordic MEDtalk.
Nocolas_gardi

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
Lung cancerNSCLCWCLC23

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
Lung cancerNSCLCWCLC23

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunotherapyLung cancerNSCLCWCLC23
Tejas Patil

Exceptional Response of Lorlatinib and Cabozantinib Combination in ROS1-Rearranged NSCLC

/ Tejas Patil
NSCLC Play the Video 07:11
Timothy F. Burns

Osimertinib for the Treatment of EGFR-Mutant NSCLC in the Adjuvant Setting

/ Timothy F. Burns
NSCLC Play the Video 10:15
Birgitte Bjørnhart

Real-World Studies Highlight NSCLC Data Gaps and Survival Differences from Randomized Controlled Trials

/ Birgitte Bjørnhart
DSKO23Lung cancerNSCLC Play the Video 5:04
Astrid Telhaug Karlsson

Survival Rates for Patients with NSCLC with Brain Metastases following Whole Brain Radiotherapy

/ Astrid Telhaug Karlsson
ELCC23Lung cancerNSCLC Play the Video 3:22
Niels Reinmuth

Current Aspects in Early-Stage NSCLC – Perspectives from ELCC23

/ Niels Reinmuth
ELCC23Lung cancerNSCLC Play the Video 3:54
Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
ESMO22Lung cancerNSCLC Play the Video 5:14
Back to top